Brief: Genfit Acquires Rights To Novel Asset From Genoscience Pharma

Genfit SA

17/12/2021 06:41

Dec 17 (Reuters) - Genfit SA  GNFT.PA :
    * ON HEELS OF GLOBAL STRATEGIC PARTNERSHIP ANNOUNCED TODAY,
GENFIT
ACQUIRES RIGHTS TO NOVEL ASSET
    * EXCLUSIVE RIGHTS FOR A NOVEL EARLY-STAGE ASSET ACQUIRED
FROM
GENOSCIENCE PHARMA IN CHOLANGIOCARCINOMA IN UNITED STATES,
CANADA AND EUROPE
    * PHASE 2 CLINICAL PROGRAM EXPECTED TO START IN 1H 2022
    * AGREEMENT COMES ON THE HEELS OF TODAY’S OTHER ANNOUNCEMENT
OF A
LONG-TERM GLOBAL STRATEGIC PARTNERSHIP WITH IPSEN INCLUDING AN
EXCLUSIVE LICENSING AGREEMENT FOR ELAFIBRANOR, A PHASE 3 ASSET
CURRENTLY EVALUATED IN PRIMARY BILIARY CHOLANGITIS
    * ALSO COMMITTED TO TAKE A EUR 3 MILLION EQUITY STAKE IN
GENOSCIENCE PHARMA THROUGH SUBSCRIPTION OF NEW ORDINARY SHARES
    * UNDER THE AGREEMENT, GENOSCIENCE PHARMA IS ELIGIBLE FOR
CLINICAL
AND REGULATORY MILESTONE PAYMENTS AND TIERED ROYALTIES
    * FIRST PAYABLE MILESTONE IS CONTINGENT ON POSITIVE PHASE 2
CLINICAL TRIAL RESULTS
    * GENFIT IS ALSO COMMITTED TO TAKE A €3 MILLION EQUITY STAKE
IN
GENOSCIENCE PHARMA THROUGH THE SUBSCRIPTION OF NEW ORDINARY
SHARES
    * WE WILL INTERACT WITH REGULATORY AGENCIES TO INVESTIGATE
ACCELERATED PATHS TO APPROVAL, POST PHASE 2 - CEO

Source text for Eikon:  ID:nGNE2Ckx54 
Further company coverage:  GNFT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))